Priority review voucher prices have doubled over three years, likely to remain high
read at Endpoints ↗RegulatoryNeutral
Recent reporting highlights that the price of FDA priority review vouchers has roughly doubled from three years ago.
The vouchers provide a shortcut that can shave about four months off the agency's standard review period, offering a speed advantage for drug launches.
Market observers say the elevated price is likely to stay high, driven by continued demand for the expedited review benefit.
The analysis was published on June 1, 2026 by FDA+Marketing.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way”
read at Endpoints ↗94 words · retrieved Jun 1
comments(0)
5-min edit window · permanent after that